Diet Containing Soy Protein Concentrate With Low and High Isoflavones for 9 Weeks Protects Against Non-alcoholic Fatty Liver Steatosis Using Obese Zucker Rats

Hakkak, Reza; Spray, Beverly J.; Børsheim, Elisabet; Korourian, Soheila

doi:10.3389/fnut.2022.913571

Cited by 11 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the current state of treatment for NAFLD/MAFLD, daidzein may be a potential therapeutic option. Recent research has demonstrated that soy protein concentrates and related isoflavones play an important role in lowering blood lipids, reducing hepatic steatosis, and improving the symptoms of NAFLD ( 66 , 67 ). A cross-section study of 17,685 US adults also showed a negative association between the consumption of flavonoids and FLI ( 68 ).…”

Section: Discussionmentioning

confidence: 99%

Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018

Yang

Gong²,

He³

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

BackgroundMetabolic associated fatty liver disease (MAFLD) has become the most common liver disease globally, yet no new drugs have been approved for clinical treatment. Therefore, we investigated the relationship between dietary intake of soy-derived daidzein and MAFLD, to find potentially effective treatments.MethodsWe conducted a cross-sectional study using data from 1,476 participants in National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018 and their associated daidzein intake from the flavonoid database in the USDA Food and Nutrient Database for Dietary Studies (FNDDS). We investigated the relationship between MAFLD status, controlled attenuation parameter (CAP), AST/Platelet Ratio Index (APRI), Fibrosis-4 Index (FIB-4), liver stiffness measurement (LSM), nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS), hepatic steatosis index (HSI), fatty liver index (FLI), and daidzein intake by adjusting for confounding variables using binary logistic regression models and linear regression models.ResultsIn the multivariable-adjusted model II, there was a negative association between daidzein intake and the incidence of MAFLD (OR for Q4 versus Q1 was 0.65, 95% confidence interval [CI] = 0.46–0.91, p = 0.0114, p for trend was 0.0190). CAP was also negatively associated with daidzein intake, β = −0.37, 95% CI: −0.63 to −0.12, p = 0.0046 in model II after adjusting for age, sex, race, marital status, education level, family income-to-poverty ratio (PIR), smoking, and alcohol consumption. Stratified by quartiles of daidzein intake, trend analysis of the relationship between daidzein intake and CAP remained significant (p for trend = 0.0054). In addition, we also found that HSI, FLI, and NFS were negatively correlated with daidzein intake. LSM was negatively related to daidzein intake but had no statistical significance. The correlation between APRI, FIB-4, and daidzein intake was not strong (although p < 0.05, β values were all 0).ConclusionWe found that MAFLD prevalence, CAP, HSI, and FLI, all decreased with increased daidzein intake, suggesting that daidzein intake may improve hepatic steatosis. Therefore, dietary patterns of soy food or supplement consumption may be a valuable strategy to reduce the disease burden and the prevalence of MAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018

Yang

Gong²,

He³

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…The SPC-LIF diet was included to test whether any observed effect was due to the protein or the isoflavone content of SPC. All diets were prepared by Archer Daniels Midland (AMD) (Decatur, IL, USA) with detailed compositions reported previously [23]. The SPC-LIF diet had 0.154 mg isoflavone/g protein with an aglycone component of approximately 0.16 mg/g protein.…”

Section: Experimental Designmentioning

confidence: 99%

“…To balance amino acid profile, L-cystine was added at 3 g/kg to the casein diet and 1.2 g/kg to SPC-LIF and SPC-HIF diets and L-methionine was added at 2.2 g/kg to SPC-LIF and SPC-HIF diets. Diets were isocaloric and isonitrogenous [23]. After 10 weeks of feeding one of the three diets (CAS, SPC-LIF, or SPC-HIF), rats were anesthetized with carbon dioxide and euthanized by decapitation.…”

Section: Experimental Designmentioning

confidence: 99%

Soy Protein Concentrate Diets Inversely Affect LPS-Binding Protein Expression in Colon and Liver, Reduce Liver Inflammation, and Increase Fecal LPS Excretion in Obese Zucker Rats

Li,

Hakkak

2024

Nutrients

Self Cite

View full text Add to dashboard Cite

Dietary soy protein and soy isoflavones have anti-inflammatory properties. Previously, we reported that feeding soy protein concentrate diet (SPC) with low or high isoflavone (LIF or HIF) to young (seven-week-old) obese (fa/fa) Zucker rats inhibits lipopolysaccharide (LPS) translocation and decreases liver inflammation compared to a casein control (CAS) diet. The current study investigated whether SPC-LIF and SPC-HIF diets would reduce liver inflammation in adult obese Zucker rats fed a CAS diet. A total of 21 six-week-old male obese (fa/fa) Zucker rats were given CAS diet for 8 weeks to develop obesity then randomly assigned to CAS, SPC-LIF, or SPC-HIF (seven rats/group) diet for an additional 10 weeks. The expression of LPS-translocation, inflammation, and intestinal permeability markers were quantified by qPCR in liver, visceral adipose tissue (VAT), and colon. LPS concentration was determined in both the colon content and fecal samples by a Limulus amebocyte lysate (LAL) test. SPC-LIF and SPC-HIF diets significantly decreased liver LPS-binding protein (LBP) expression compared to CAS diet (p < 0.01 and p < 0.05, respectively). SPC-HIF diet also significantly decreased liver MCP-1 and TNF-α expression (p < 0.05) and had a trend to decrease liver iNOS expression (p = 0.06). In the colon, SPC-HIF diet significantly increased LBP expression compared to CAS diet (p < 0.05). When samples from all three groups were combined, there was a negative correlation between colon LBP expression and liver LBP expression (p = 0.046). SPC diets did not alter the expression of intestinal permeability markers (i.e., occludin, claudin 3, and zonula occludens-1) in the colon or inflammation markers (i.e., TNF-α and iNOS) in VAT or the colon. LPS levels in the colon content did not differ between any groups. Fecal LPS levels were significantly higher in the SPC-LIF and SPC-HIF groups compared to the CAS group (p < 0.01). In conclusion, SPC, particularly SPC with HIF, reduces liver LBP expression and inflammation makers (i.e., TNF-α and MCP-1 expression) in adult obese Zucker rats, likely by reducing LPS translocation.

show abstract

“…Whereas obese rats had significantly greater liver steatosis score than lean rats, both soy protein concentrate with low isoflavones and and soy protein concentrate with high isoflavones intake resulted in reduction in steatosis score compared to control group. Authors also suggested that soy protein concentrate with isoflavones consumption may protect against liver steatosis and these results are greater with a higher concentration of isoflavones [27].…”

Section: Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

Impact of soy isoflavones on the prevention and treatment of obesity

Wąsik,

Tomaszuk,

Wojtuś

2024

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose: Currently, as the frequency of obesity is alarming, the role of many factors that could contribute in preventing and treating this condition are being researched, among them the certain food with beneficial health profiles - one of them is soybeans, specifically the isoflavones it contains. Populations that consume soy are known for lower risk of various disorders - among them obesity. The aim of this paper is to summarize the existing paper about the role of these bioactive components in the treatment of this condition. The search was conducted using PubMed and Google Scholarship databases. Brief description of the state of knowledge: Obesity is one of the leading challenges in today’s healthcare as it leads to various chronic diseases that are fraught in consequences. Current knowledge is pointing into the association between composition of the soy isoflavones and the lower risk of obesity. Results of the studies indicate that patients affected with obesity could benefit from introducing soy isoflavones into their diet along with other necessary modifications. Conclusions: Soy isoflavones are potential agents in the holistic obesity treatment. Consumption of isoflavones merits further recognition as foregoing results of conducted studies are pointing to its possibly meaningful role. It is worth mentioning that consumption of soy isoflavones is not only an anti-obese factor, but also presents various other health benefits and when consumed rationally poses no risk to human’s well being. We conclude that further studies would enable us to fully reveal the potential of those polyphenols.

show abstract

Diet Containing Soy Protein Concentrate With Low and High Isoflavones for 9 Weeks Protects Against Non-alcoholic Fatty Liver Steatosis Using Obese Zucker Rats

Cited by 11 publications

References 38 publications

Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018

Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018

Soy Protein Concentrate Diets Inversely Affect LPS-Binding Protein Expression in Colon and Liver, Reduce Liver Inflammation, and Increase Fecal LPS Excretion in Obese Zucker Rats

Impact of soy isoflavones on the prevention and treatment of obesity

Contact Info

Product

Resources

About